Beyond The Numbers: 7 Analysts Discuss Alpine Immune Sciences Stock
Portfolio Pulse from Benzinga Insights
Alpine Immune Sciences (NASDAQ:ALPN) has been the subject of diverse analyst ratings over the past three months, with 7 analysts offering views ranging from bullish to bearish. The average 12-month price target has increased by 37.28% to $24.71, with a high estimate of $32.00 and a low of $18.00. Analysts from firms like HC Wainwright & Co., Wedbush, RBC Capital, Morgan Stanley, and Berenberg have adjusted their ratings and price targets, reflecting a positive outlook on the company's performance. Alpine Immune Sciences is a clinical-stage biopharmaceutical company with a focus on protein-based immunotherapies. Despite a market capitalization below industry benchmarks, the company has seen a revenue growth of 20.03% and has a strong net margin and ROE, with minimal reliance on debt financing.
December 22, 2023 | 12:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Alpine Immune Sciences has received positive analyst ratings and an increased average price target, indicating a bullish sentiment. The company's strong financial performance and revenue growth are likely to contribute to investor confidence.
The positive shift in analyst ratings and the significant increase in the average price target suggest that the market's perception of Alpine Immune Sciences is improving. This could lead to increased investor interest and potentially a rise in the stock price in the short term. The company's strong financial metrics, such as revenue growth and net margin, support this positive outlook. However, as analyst ratings are subjective opinions, the actual impact on the stock price can vary.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100